These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 22348670

  • 21. Current concepts and management approaches in nonalcoholic fatty liver disease.
    Attar BM, Van Thiel DH.
    ScientificWorldJournal; 2013; 2013():481893. PubMed ID: 23576902
    [Abstract] [Full Text] [Related]

  • 22. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E.
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [Abstract] [Full Text] [Related]

  • 23. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
    Boettcher E, Csako G, Pucino F, Wesley R, Loomba R.
    Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
    [Abstract] [Full Text] [Related]

  • 24. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 25. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC, Larter CZ.
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [Abstract] [Full Text] [Related]

  • 26. The treatment of NAFLD.
    Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C, Capasso R, Coppola F, Dauria M, Loguercio C.
    Eur Rev Med Pharmacol Sci; 2005 Feb; 9(5):299-304. PubMed ID: 16231594
    [Abstract] [Full Text] [Related]

  • 27. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 28. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A, Akhter A.
    Ann Hepatol; 2017 May; 16(4):538-547. PubMed ID: 28611274
    [Abstract] [Full Text] [Related]

  • 29. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM, Sterling RK.
    Aliment Pharmacol Ther; 2006 Jan 15; 23(2):207-15. PubMed ID: 16393299
    [Abstract] [Full Text] [Related]

  • 30. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M, Kawaguchi K, Korenaga K, Uchida K, Sakaida I.
    Nihon Rinsho; 2006 Jun 15; 64(6):1157-64. PubMed ID: 16768125
    [Abstract] [Full Text] [Related]

  • 31. Emerging drugs for non-alcoholic fatty liver disease.
    Federico A, Niosi M, Vecchio Blanco CD, Loguercio C.
    Expert Opin Emerg Drugs; 2008 Mar 15; 13(1):145-58. PubMed ID: 18321154
    [Abstract] [Full Text] [Related]

  • 32. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.
    Pol Merkur Lekarski; 2008 Jun 15; 24(144):568-71. PubMed ID: 18702346
    [Abstract] [Full Text] [Related]

  • 33. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M, Loomba R.
    Curr Opin Gastroenterol; 2014 May 15; 30(3):223-37. PubMed ID: 24717764
    [Abstract] [Full Text] [Related]

  • 34. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
    Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J.
    Curr Pharm Des; 2013 May 15; 19(29):5280-96. PubMed ID: 23394096
    [Abstract] [Full Text] [Related]

  • 35. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRN.
    N Engl J Med; 2010 May 06; 362(18):1675-85. PubMed ID: 20427778
    [Abstract] [Full Text] [Related]

  • 36. Future therapy for non-alcoholic fatty liver disease.
    Issa D, Patel V, Sanyal AJ.
    Liver Int; 2018 Feb 06; 38 Suppl 1():56-63. PubMed ID: 29427492
    [Abstract] [Full Text] [Related]

  • 37. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
    Mahady SE, Wong G, Craig JC, George J.
    Hepatology; 2012 Dec 06; 56(6):2172-9. PubMed ID: 22707355
    [Abstract] [Full Text] [Related]

  • 38. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 39. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM.
    Aliment Pharmacol Ther; 2008 Jul 07; 28(1):2-12. PubMed ID: 18410557
    [Abstract] [Full Text] [Related]

  • 40. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S, Jensen D, Hart J, Mohanty SR.
    Liver Int; 2013 Oct 07; 33(9):1398-405. PubMed ID: 23763360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.